Anaptysbio (ANAB) Announces Portfolio Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
January 5, 2023 4:05 PM ESTAdvancing rosnilimab, its PD-1 agonist, into a global Phase 2b trial to treat rheumatoid arthritis with study initiation in Q3 2023Advancing ANB032, its BTLA agonist, into a global Phase 2b trial to treat atopic dermatitis with study initiation in Q2 2023Advancing rosnilimab into a second Phase 2 trial, in an indication to be announced, with study initiation anticipated by year-end 2023Blinded interim review of alopecia areata Phase 2a data demonstrated rosnilimab proof of mechanism with robust reductions in... More
